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ABSTRACT   
 
Neuregulin 1 (NRG1), a ligand for HER3 and HER4 receptors, is secreted by both pancreatic tumor 
cells (PC) and cancer-associated fibroblasts (CAFs), the latter representing the most abundant 
compound of pancreatic stroma. This desmoplastic stroma contributes to Pancreatic Ductal 
Adenocarcinoma (PDAC) aggressiveness and therapeutic failure by promoting tumor progression, 
invasion and resistance to chemotherapies. In the present work, we aimed at disrupting the complex 
crosstalk between PC and CAF in order to prevent tumor cell proliferation. To do so, we demonstrated 
the promising tumor growth inhibitory effect of the 7E3, an original antibody directed to NRG1. This 
antibody promotes antibody dependent cellular cytotoxicity in NRG1-positive PC and CAFs and 
inhibits NRG1-associated signaling pathway induction, by blocking NRG1-mediated HER3 
activation. Moreover, 7E3 inhibits migration and growth of pancreatic cancer cells co-cultured with 
CAFs, both in vitro and in vivo using orthotopic pancreatic tumor xenografts. Our preclinical results 
demonstrate that the anti-NRG1 antibody 7E3 could represent a promising approach to target 
pancreatic stroma and cancer cells, thereby providing novel therapeutic options for PDAC. 
 
 
Key words: immunotherapy, neuregulin 1, HER3, pancreatic cancer, cancer-associated fibroblast 
 
 
Abbreviations: PC: pancreatic cancer, CM: condition medium, CAF: cancer associated fibroblast 
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1. INTRODUCTION  
Pancreatic cancer remains one of the most aggressive tumors with an extremely poor prognosis and 
is estimated to become the second leading cause of cancer-related death by 2030 1, 2. This 
dramatic outcome is related to the lack of efficient therapeutic tools, early diagnostic markers, and 
high resistance to chemotherapy.  
Abundant desmoplastic reaction is a prominent feature of pancreatic cancer and constitutes up to 80% 
of the total tumor volume. It is characterized by the presence mainly of cancer-associated fibroblasts 
(CAFs), but also of immune cells, vasculature, and extracellular matrix (ECM). These stroma 
characteristics contribute to pancreatic cancer aggressivity and therapeutic failure because they 
promote tumor progression, invasion and resistance to chemotherapies 3, 4. Once activated, CAFs 
express alpha smooth muscle actin (SMA) and secrete ECM and soluble factors (e.g., growth and 
inflammatory factors) that stimulate tumor growth and mediate inflammation. In preclinical studies, 
stroma disruption, by direct CAF targeting (hedgehog signaling inhibitors) 5 or by ECM enzymatic 
digestion (hyaluronidase), results in tumor inhibition and increases drug delivery 6; however, 
controversial or disappointing results were reported by clinical trials. Moreover, recent studies have 
questioned CAF role in pancreatic tumor maintenance and highlighted the need of caution when 
targeting CAFs 7-9. Indeed, several evidences indicate that there are different CAF subtypes with 
different functions 10, 11. Therefore, characterization of these subtypes is needed to enable the 
specific targeting of CAFs with pro-tumor features. 
Neuregulins (NRGs) are large polypeptide growth factors that are part of the EGF family of proteins. 
They are encoded by four genes (NRG1-4) that are subject to extensive alternative mRNA splicing, 
leading to more than 30 variants grouped in six types (I-VI) with a distinct N-terminal part. NRG1 and 2 
are both HER3 and HER4 ligands and have at least two splice alternatives in their EGF-like domains, 
resulting in α and β isoforms. NRG1 β has higher binding affinity for HER3 through HER2-dependent 
recruitment 12. NRG3 and 4 bind only to HER4. Most isoforms are synthetized as transmembrane 
molecules with the EGF-like domain in the extracellular space and are released as soluble factors by 
cell surface proteases. Binding to the EGF-like domain of NRG1 promotes HER3 or HER4 
conformational changes, leading to their dimerization and activation that result in the phosphorylation 
of downstream signaling molecules. Several evidences indicate that NRG1 contributes to the 
development and progression of different tumor types, such as breast, prostate or pancreatic cancer 
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[13-16. High NRG1 expression has been correlated with poor prognosis in breast cancer, head and 
neck squamous cell carcinoma and pancreatic cancer 13-15. In addition, NRG1 downregulation by 
antisense oligonucleotides, or NRG1 signaling inhibition by competitive binding of a shorter HER3 
isoform reduces breast cancer cell proliferation and migration [16, 17. Furthermore, the crosstalk 
between NRG1 and HER3 is involved in resistance to chemo- and targeted therapies through the 
maintenance of oncogenic signaling pathways [18. 
Several studies reported that not only EGF family growth factors but also their receptors play an 
important role in pancreatic cancer development. Expression of EGFR, HER2 and HER3 has been 
examined in pancreatic ductal carcinoma and correlated with advanced disease and poor prognosis 
[19-22. HER4 expression has not been examined as extensively and its prognostic value is not 
known. 
Disruption of intracellular communications between stromal and cancer cells could affect tumor 
proliferation and represents an interesting therapeutic strategy. In this context, we hypothesized that 
targeting NRG, which we here show to be secreted both by CAFs and tumor cells, could be a novel 
therapy to overcome CAF-triggered tumor growth in pancreatic cancer. Here, we investigated, in in 
vivo and in vitro co-culture of pancreatic cancer cells and CAFs, the therapeutic potential of an original 
monoclonal antibody (7E3) that targets NRG1 Ig-like domain. We show promising tumor growth 
inhibitory effects of this antibody which promotes antibody dependent cellular cytotoxicity (ADCC) in 
NRG1-permeated pancreatic cancer cells and in NRG1-positive CAFs and blocks NRG1-mediated 
HER3 activation and downstream signaling pathway induction. 
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2. MATERIALS AND METHODS  
 
2.1. Cell lines and reagents 
The BxPC-3, CFPAC-1, HPAC, AsPC-1, SW1990, MiaPaCa-2 and MCF7 cancer cell lines were 
obtained from ATCC (Rockville, MD, USA) and cultured following the ATCC recommendations. The 
identity of cell lines was confirmed by genetics authentification test (Eurofins, Ebersberg).  BxPC-3-
Luc, HPAC-Luc, shHER3 BxPC-3 and shluc BxPC-3 cells were generated previously in the laboratory 
[23. Stably-transfected AsPC-1-Mock (vector alone) and AsPC-1-NRG1 cells were obtained as 
previously described for pMSCV-hygro-NRG1(OriGene) [24.  
RhNRG11-ECD and HER3-Fc were purchased from RD Systems (Minneapolis, MN). All antibodies 
used in western blot were from Cell Signaling Technology (Beverly, MA). Antibodies against HER3 
(16D3-C1) and CEA (35A7) were generated previously in the laboratory [25. 
2.2. Human CAF isolation and cell culture 
CAFs were isolated from human PDAC samples using the outgrowth method described by Duluc [26. 
CAFs were cultured in Dulbecco’s modified Eagle’s medium F12 (DMEM/F12) with 10% de-
complemented fetal calf serum (FCS, Life Technologies). CAF-CM was recovered from 10
6
 CAFs 
cultured in DMEM/F12 without FCS for 48 hours. Primary normal pancreatic fibroblasts were kindly 
provided by Corinne Bousquet (CRCT, Toulouse). Normal Pancreatic Cells (NPC) were obtained from 
healthy human specimen from ICM hospital (Montpellier). 
2.3. Quantitative PCR for NRG1 expression analysis  
RNA was isolated using the Quick-RNA MiniPrep Kit (Zymo Research Corp., Irvine, CA) according to 
the manufacturer’s protocol. RNA samples were first reverse-transcribed using the SuperScript III 
reverse transcriptase (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s 
protocol. Gene expression was then assessed by quantitative PCR using the Light Cycler 480 SYBR 
Green I Master Mix (Clontech). The primer sequences used for hNRG1 are Forward 5’-
ACCAGAAGAGAGTGCTGACC-3’ Reverse 5’-CCAGAAGAGAGTGCTGACCA-3’ and Forward 5’-
CCACTGGGACAAGCCATCTT-3’ Reverse 5’- TTCACCATGAAGCACTCCCC-3’. Concentrations of 
mRNA were normalized to the concentration of the housekeeping gene HPRT, and 
expressed relatively to the lower cells expressing NRG1 (CFPAC=1). 
2.4. NRG1 secretion analysis 
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Conditioned medium were analyzed using the NRG1 1 human ELISA kit (Abcam) according 
the manufacturer instructions. Concentrations were calculated from standard curve and data 
are representative of two independent experiments. 
2.5. Generation of monoclonal antibodies 
BALB/c mice were immunized with 10 g rhNRG11-EDC by subcutaneous injection as described 
previously [25. Antibodies were produced by Biotem (Apprieu, France) and stored at -20°C in 
phosphate buffered saline (PBS). 
2.6. Epitope mapping 
213 overlapping dodecapeptides that were frame-shifted by one or three residues and that covered 
the entire amino acid sequence of human NRG1 ECD were synthesized on cellulose membrane 
and epitope mapping was performed as already described [23. For SPOT alanine scanning analysis, 
three pentadecapeptides corresponding to the identified antibody-immunoreactive sequences and the 
13 alanine analogs of each peptide were synthesized by using the SPOT method. The antibody 
reactivity of cellulose-bound peptides was assayed as described above. SPOT reactivity was 
evaluated by scanning the membranes and measuring the spot intensities with ImageJ 1.44 
(http://rsbweb.nih.gov/ij).  
2.7. Western blot analysis 
Western blotting was performed using cell protein lysates as described previously [49. Band intensity 
was analyzed with the G:BOX imaging system (Syngene,Cambridge, UK). 
2.8. Cell proliferation assay  
The effect of the anti-NRG1 antibody 7E3 on cell proliferation and cell viability was evaluated using 
luciferase activity assays and sulforhodamine B (SRB) colorimetric assays, respectively. Cells were 
incubated with serum-free medium for 24h and with RhNRG1β1-ECD  and antibodies. After 5 days of 
incubation, the luciferine substrate (Promega, Madison, WI) added to the cells. Bioluminescence was 
determined using the Wallac Trilux 1450 Microbeta liquid scintillation and luminescence counter 
(Perkin-Elmer, Wellesley, MA). For SRB revelation, cells were fixed with cold 10% trichloroacetic acid 
and stained with SRB (Sigma, St Louis, MO). The protein-bound dye was dissolved in 10mM 
unbuffered Tris base solution, and the OD540 was read using a microplate reader. Growth inhibition 
was calculated based on the percentage of proliferating cells in treated samples relative to untreated 
cultures. All experiments were performed three times. 
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2.9. Cell migration (wound healing) assay 
Cells were seeded in 6-well plates and grown at 37°C in RPMI medium with 10% FBS as previously 
described [27. Cells were incubated in serum-free medium with rhNRG1β1-ECD and/or 7E3 or IR 
antibody. Cell migration was observed 48h after and images captured using a Nikon TS100 
microscope and an Olympus SP-510 UZ camera.  
2.10. 3D-growth assay 
Cells were washed in PBS, trypsinized, and prepared in RPMI with 2% FCS and 20% methyl cellulose 
for spheroid formation in ultra-low attachment 96-well black plates. After 24h, cells were incubated 
with 50ng/ml of rhNRG1β1-ECD and 50-100µg/ml of 7E3 or IR antibody. After 10 days of incubation, 
25µl of calcein-EthD-1 master mix was added to each well. After 30min, fluorescence was counted 
and cells analyzed with a Celigo Image Cytometer using the “Tumorosphere” application for spheroid 
area measurement (Nexcelom Bioscience, Lawrence, MA). All experiments were performed three 
times. 
2.11. Antibody internalization  
Cells were grown with serum-free medium for 24h and were then incubated or not with 50 ng/ml 
rhNRG11-ECD for 10min and then with 30µg/ml of anti-NRG1, -HER3, -CEA antibodies or RPMI 
alone (negative control) at 4°C or 37°C. At different time points, cells were fixed and permeabilized in 
3.7% formaldehyde/PBS, saturated with PBS/1%BSA and finally incubated with AlexaFluor 488-
conjugated goat anti-mouse IgGs (1:100) (Cell Signaling Technology, Danvers, MA). Coverslips were 
mounted with EverBrite
TM
 Hardest Mounting Medium with DAPI (Biotium, Inc., Fremont, CA) and 
analyzed the day after with a Zeiss Axioplan 2 Imaging microscope.  
2.12. Immunofluorescence 
Fibroblasts were plated on coverslips in RPMI medium with 10% FBS at 37°C. Two days after, cells 
were fixed and permeabilized with 3.7% formaldehyde/PBS, saturated with PBS/1%BSA and finally 
incubated with a monoclonal anti-vimentin Cy3 conjugate (1:600) or anti-actin or -SMA FITC 
conjugates (1:100) (Sigma).  
2.13. Surface Plasmon Resonance analysis 
SPR experiments were performed using a Biacore T200 and a Biacore 3000 instrument as already 
described [48. Briefly, HER3-Fc was captured on the CM5 sensor chip surface (2200 RU) using the 
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anti-human Fc Capture Kit from GE Healthcare (Chicago, IL). Then, rhNRG11-ECD was injected at 
185nM followed by an injection of 200nM 7E3 antibody or buffer at 30µl/min.  
2.14. ADCC assay 
LDH release was investigated with the CytoTox Non-Radioactive Cytotoxicity Assay (Promega). Sh-
luc BxPC-3 or sh-HER3 BxPC-3 cells were incubated with 50 ng/ml rhNRG11-ECD plus 50 g/ml 
7E3 or IR antibody for 30min, then hPBMC isolated with Ficoll from samples purchased from 
Etablissement Français du Sang (Montpellier, France) were added to the wells at a ratio of 1/15 
(target:effector) for 24h. The same assay was done with CAFs without rhNRG11-ECD. The cell lysis 
percentage was calculated using the following formula: (bioluminescence at the experimental point - 
basal bioluminescence) / (total lysis bioluminescence – basal bioluminescence) X 100. The basal 
luminescence value corresponded to cells incubated with hPBMC alone, and the total lysis 
bioluminescence value was obtained after cell incubation with 0.1% SDS for 30min. 
2.15. Tumor xenografts and treatment  
All in vivo experiments were performed in compliance with the French regulations and ethical 
guidelines for experimental animal studies in an accredited establishment (Agreement No. C34-172-
27). Pancreatic cancer cells (3.5x10
6
) were injected subcutaneously into the right flank of 6-week-old 
female athymic mice, purchased from Envigo (Le Malcourlet, France). Tumor-bearing mice were 
treated with 10 mg/kg of 7E3 or IR antibody by intraperitoneally injection twice a week for 4 or 6 
weeks. Tumor volumes were calculated by using the formula: D1 x D2 x D3 /2.  
For orthotopic xenografts, 1x10
6
 BxPC-3-Luc cells in 30 l PBS were injected in the pancreas of 
athymic mice, and 7 days post-graft, mice were treated as indicated above, but for 6 weeks. Tumor 
growth was monitored by bioluminescence detection as described previously [28. At the end of the 
experiment (maximum bioluminescence signal in untreated animals), mice were sacrificed and 
bioluminescence in pancreas measured. For orthotopic co-xenograft experiments, a 1:2 mixture of 
BxPC-3 cells and CAFs was injected in the pancreas of athymic mice. Treatment started one weeks 
after grafting after randomization in two groups. Tumor growth was monitored by high-resolution 3D 
ultrasonic imaging (Vevo2100®, VisualSonics Inc.) using a Vevo2100 ultrasound scanner with a 
MS550D probe (22-55 MHz). Each tumor was scanned using 3D mode under respiratory gating. The 
3D images of the tumor were manually contoured along the tumor margin throughout the 3D stack. 
The tumor volume was measured using parallel segmentation in the Vevo2100 software (version 3.0, 
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VisualSonics Inc.). At the end of the experiment, the pancreas were weighted.  
2.16. Immunohistochemistry 
Immunohistochemistry was performed as described previously [27. Quantification was done with 
Image Scope software.  
2.17. Statistical Analysis   
Statistical analysis of in vivo experiments was performed using the STATA 11.0 software (StataCorp., 
College Station, TX) as previously described [28.  
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3. RESULTS 
 
3.1. NRG1 regulates pancreatic tumor growth in an autocrine and paracrine manner 
RT-qPCR expression analysis showed NRG1 expression in 17/33 (51.5%) pancreatic tumor samples 
(Figure 1A). Then, NRG11 gene expression was assessed in five KRAS-mutated pancreatic cancer 
cell lines and one KRAS-wild type cell line (BxPC-3). BxPC3, CFPAC and SW1990 cells expressed 
NRG1, whereas HPAC, MiaPaca2 and AsPC-1 did not (Figure 1B). As positive control, we developed 
a NRG1 positive cell derived of AsPC-1 (AsPC-1-NRG1 cells). As negative control, we used normal 
pancreatic cells (NPC). By ELISA, we measured the concentration of NRG1 secretion in medium. This 
expression correlated this NRG1 mRNA expression.  As previously described [23., all cell lines, with 
the exception of MiaPaCa-2 cells, expressed HER3, but not HER4. 
NRG1 role in pancreatic tumor cell growth was supported by the finding that cell growth was higher 
(2.5-fold) in AsPC-1-NRG1 cells than in AsPC-1-Mock cells (Figure 1C, middle panel). Similarly, 
AsPC-1-NRG1 tumors collected 40 days after cell xenograft in mice were heavier than AsPC-1-Mock 
tumors (mean weight: 1.26g vs 0.73g; p=0.0117) (Figure 1C, lower panel).  
Interestingly, we observed that CAFs isolated from pancreatic ductal adenocarcinoma (PDAC) 
specimens, also expressed NRG11 (Figure 1D). After 10 days of culture, CAFs exhibited a fibroblast-
like phenotype, as shown by immunofluorescence expression of vimentin in sample CAF11, and were 
considered as activated, based on SMA expression (Figure 1D). In comparison, normal pancreatic 
fibroblasts (NPF) expressed vimentin, but not SMA, and therefore, were considered as not activated 
(Figure 1D). NRG1 mRNA was expressed in five of the six CAF preparations (Figure 1E). Conditioned 
medium (CM) from these CAF cultures expressed NRG1 as measured by ELISA assay and induced 
phosphorylation of HER3 in BxPC-3 cells (Figure 1F), except for the CM from CAF8 that did not 
express NRG1.  
Altogether, these results demonstrated that NRG1 is expressed in both pancreatic tumor cells and 
CAFs and regulates pancreatic tumor growth in an autocrine or paracrine manner. 
 
3.2. The NRG1-specific antibody 7E3 binds to NRG1 Ig-like domain and promotes ADCC towards 
pancreatic cancer cells in which NRG1 is complexed with HER3 
The specific anti-NRG1 antibody 7E3 was generated by immunizing mice with recombinant human 
NRG11 extracellular domain (rhNRG11-ECD). 7E3 bound to NRG11-ECD, but not to the EGF 
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domain of NRG1 and NRG1, NRG13 SMDF nor to the related growth factors EGF, GAS6, AREG 
and HB-EGF (Supplementary Figure 1A). Surface plasmon resonance (SPR) analysis showed that 
7E3 bound to rhNRG11-ECD with an affinity of 1.05nM (Supplementary Figure 1B), close to that of 
NRG1 binding to HER3 (1.6 nM). However, 7E3 still bound to recombinant NRG1 pre-complexed with 
HER3-Fc with similar affinity as for NRG1 alone (Figure 2A). This suggested that besides its ligand 
trapping activity, 7E3 could also be used to target HER3-bound NRG1. This was confirmed by 
immunofluorescence cell analysis, measuring 7E3 ability to recognize NRG1 when bound to HER3 at 
the cell surface of BxPC-3 cells expressing or not HER3 upon HER3 silencing (shHER3 BxPC-3 cells 
shLuc BxPC-3 control cells) (Figure 2B). The 7E3 antibody bound to rhNRG11-ECD complexed to 
membrane-expressed HER3 in shLuc BxPC-3, but not in shHER3 BxPC-3 cells.  
Using the SPOT method, we identified the epitope recognized by 7E3 located in the IgG-like domain 
of NRG11 N-terminus. This explains why 7E3 still binds to NRG1 complexed to HER3, this 
NRG1/HER3 interaction requiring the EGF-like domain of NRG1. This also explains why 7E3 does not 
bind to the EGF domain of NRG1 or of NRG1, nor NRG13 SMDF which does not contain the Ig-
like domain (Supplementary Figure 1A). Alanine scanning analysis (Figure 2C) indicated that the 
154
IRISV
158
 sequence in NRG1 Ig-like domain was the binding motif and residues R
155
 and V
158
 the 
main contributors.  
As 7E3 can bind to NRG1 complexed to HER3, ADCC assays, were performed to test whether 7E3 
could activate immune cells (Figure 2D). To do so, human peripheral blood mononuclear cells 
(hPBMC) were used as effector cells, and shHER3 or shLuc BxPC-3 cells as target cells, Co-
incubation of 7E3 with rhNRG11-ECD (to mimic NRG1 expressed by CAFs) strongly increased 
ADCC of shLuc BxPC3 cells compared to 7E3 alone. Similar results were obtained with trastuzumab 
(positive control) (Figure 2D). Upon HER3 silencing, ADCC was not induced by incubation with 7E3, 
with or without rhNRG11-ECD. Thus, 7E3 bound to NRG1 Ig-like domain pre complexed with HER3 
favors ADCC in pancreatic cancer cells. 
 
3.3. 7E3 blocks NRG1-mediated HER3 signaling and downstream AKT/MAPK phosphorylation, and 
promotes HER3 downregulation in pancreatic cancer cells 
As expected, incubation of BxPC-3 and MCF7 cells with rhNRG11-ECD induced phosphorylation of 
HER3 and of the downstream AKT and MAPK kinases (Figure 3A). This effect was inhibited by 7E3, in 
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a dose-dependent manner. Similarly, CM from NRG1-expressing BxPC-3 cells induced HER3, AKT 
and MAPK phosphorylation in MCF7 breast cancer cells (HER3-expressing but not NRG1) 
(Supplementary Figure 2A). This effect was blocked by 7E3 demonstrating 7E3 inhibitory effect on 
NRG1 secreted by cancer cells. Moreover, 7E3 inhibited NRG1-mediated HER4 phosphorylation in 
IGROV-1 ovarian cancer cells (HER3-negative and HER4-positive) (Figure 3B).  
To test whether 7E3 internalization mediated HER3 downregulation in pancreatic cancer cells, BxPC-3 
cells were incubated with 7E3 and rhNRG11-ECD at different time points. Co-incubation with 7E3 
and rhNRG11-ECD led to antibody binding and internalization that started at 30min and peaked at 
60min at 37°C (Figure 3C). Conversely, antibody internalization was abrogated at 4°C. This was 
confirmed by immunofluorescence analysis after a 60min-incubation with fluorescein-labeled 7E3 
(Figure 3C). Moreover, co-incubation with 7E3 and rhNRG11-ECD induced HER3 downregulation in 
BxPC-3 cells from 10h until 48h (end of the experiment) (Figure 3D).  
Here we demonstrated that 7E3 acts by inhibiting HER3 activity and by directly down regulating HER3 
expression. 
 
3.4. 7E3 inhibits viability, growth and migration of pancreatic cancer cells  
As NRG1 plays a role in cell proliferation, the viability of HPAC and BxPC-3 cells was assessed after 
co-incubation with 7E3 and rhNRG11-ECD, in 2D-cell monolayer cultures (Figure 4A). 7E3 
significantly reduced cancer cell viability (between 7% and 35% of inhibition) in a dose-dependent 
manner. Moreover, 100 g/ml 7E3 alone also reduced by 20% cell viability of NRG1-positive BxPC-3 
cells (Supplementary Figure 2A). The IR antibody did not affect cell viability in any of these 
experimental conditions. In 3D-cell cultures (Figure 4B), co-incubation with rhNRG11-ECD and 7E3 
strongly inhibited spheroid growth by about 67% compared with rhNRG11-ECD alone, as indicated 
by the reduction of the calcein-positive spheroid area. In wound-healing assays (Figure 4C), exposure 
of BxPC-3 and HPAC cells to rhNRG11-ECD after wounding increased cell migration in comparison 
with untreated cells, resulting in the complete wound closure at 48h post-wound. Conversely, co-
incubation with rhNRG11-ECD and 10 or 100 g/ml of 7E3, but not with IR antibody, strongly 
inhibited cell migration and wound healing (Figure 4C).  
 
3.5. 7E3 reduces pancreatic tumor growth in mice 
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The in vivo efficacy of 7E3 was evaluated in mice xenografted subcutaneously with BxPC-3 cells 
(NRG1-positive) (Figure 4D). Injection of 7E3 significantly reduced tumor growth compared with the IR 
antibody (control) (p=0.020). As pancreatic cancer is characterized by poor vascularization, dense 
microenvironment and reduced drug penetration, the in vivo effect of 7E3 was also studied in an 
orthotopic pancreatic cancer model (Figure 4E). One week after injection in mice of BxPC-3-Luc cells, 
the pancreas bioluminescence signal (to follow cancer cell growth) was measured, and then mice 
were treated with 7E3 or IR antibody (control). The bioluminescence signal remained significantly 
lower in all 7E3-treated mice compared with controls (p=0.047) (Figure 4E). At day 48 post-graft, 
bioluminescence was still very low in 7E3-treated mice in comparison with control (p=0.0404) 
(supplementary Figure 2C). These results demonstrated that 7E3 slows down the growth of NRG1-
positive pancreatic tumors. Inhibition of AKT and MAPK phosphorylation was observed by Western 
blot analysis in 7E3 treated subcutaneous tumors in contrast to control tumors (Figure 4F). 
 
3.6. 7E3 induces pancreatic CAF lysis in the presence of hPBMC and inhibits pancreatic cancer cell 
proliferation promoted by CAFs secreted NRG1 
To assess 7E3 effect on pancreatic epithelial cancer cells associated with the surrounding cells, 
primary CAFs isolated from six human PDAC specimens (Figure 1D) were used. 7E3 could bind to 
CAFs, as indicated by immunofluorescence analysis of CAF11 and CAF12 cultures (Figure 5A), 
consistent with NRG1 expression by these CAFs (Figure 1D). Incubation of BxPC-3 cells with CM 
from CAF11 and CAF12 (CAF-CM) strongly induced HER3 phosphorylation that was inhibited by 7E3, 
but not the IR antibody (Figure 5B). Similar results were obtained with CAF3, 4, 5 and 6 
(Supplementary Figure 3A). Incubation of CAF12 with hPBMC and 7E3, but not the IR antibody, 
induced ADCC (Figure 5C), albeit weakly, probably due to dynamic NRG1 cleavage at the cell surface 
by metalloproteinases [17. Moreover, different CAF-CMs increased BxPC-3 cell viability in 2D-
monolayer culture, compared with cells incubated with medium alone (with 1% FCS) (Figure 5D and 
Supplementary Figure 3B). Addition of 7E3, but not of the IR antibody, decreased significantly this 
effect (p<0.001 for CAF5, 6 and 11-CM), except in BxPC-3 cells incubated with CAF8-CM that was 
recovered from the NRG1-negative CAF8 culture (Figure 1D). Finally, bioluminescence measures in 
HPAC-Luc cells co-cultured with CAF11 in a 3D culture system (Figure 5E) showed that incubation 
with 7E3, but not the IR antibody, reduced HPAC-Luc cell viability in a dose-dependent manner.   
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3.7. 7E3 inhibits BxPC-3 tumor growth in nude mice after orthotopic co-injection of BxPC-3 cells and 
CAFs  
To reconstitute in vivo the human pancreatic tumor microenvironment, NRG1-positive BxPC-3 cells 
and NRG1-positive CAF11 cells (1:2 ratio) were co-xenografted in the pancreas of mice and tumor 
growth was followed by ultrasonography. In this orthotopic mouse model, 7E3 treatment significantly 
reduced the growth of reconstituted CAF stroma/BxPC-3 tumors (Figure 6A, supplementary figure 4A) 
compared with controls (no treatment) (p=0.003). This result was confirmed by the finding that at day 
60 (end of the experiment), the mean tumor weight was 44% lower in 7E3-treated mice than in 
controls (p=0.032) (Figure 6B). IHC analysis of tumors shown the presence of SMA positive 
fibroblasts (marker of activated CAF) in tumors and an increased expression of cleaved caspase 3 (in 
tumor cells), a marker of apoptosis, whereas KI67 index (marker of proliferation) was unchanged 
(Supplementary Figure 4B) in the antibody treatment tumors vs control (Figure 6C). 
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4. DISCUSSION 
The 7E3 antibody blocked NRG1-dependent tumor cell growth by decreasing HER3 activity and 
expression level and promoting ADCC activation against tumors cells and micro-environment. This 
mechanism can contribute to the therapeutic effect observed in mice and can be explained by its 
original binding. Indeed, our antibody exhibited a high degree of specificity and affinity for NRG1 IgG-
like domain, and did not prevent the NRG1 binding to HER3. This explains 7E3 ability to target NRG1 
already linked to its receptor and to induce ADCC. This binding feature has never been described and 
is completely different from the one displayed by other anti-NRG1 antibodies, which are mostly 
directed to the EGF-like domain and only act by ligand trapping [29. Ligand trapping has already been 
evaluated and validated in the clinic in colorectal, lung and breast cancer with the anti-VEGF antibody 
bevacizumab (30). Pre-clinical projects which aimed at targeting with antibodies other EGFR ligands, 
such as HB-EGF, TGF and amphiregulin [31, 32, only proposed a strategy of ligand sequestration, 
without affecting ligand/receptor complexes as we demonstrated in this study. 
The pernicious ability of pancreatic cancer cells to collaborate with the stroma to access resources, 
such as growth factors and metabolites, is described in numerous studies. Here, we demonstrate how 
the resulting tumor growth can be efficiently reduced by disturbing the crosstalk between pancreatic 
tumor cells and CAFs with our anti-NRG1 antibody 7E3. Moreover, 7E3 decreases the viability of 
NRG1-positive pancreatic cancer cells also in conditions where NRG1 is secreted by the stroma 
compartment, for instance CAFs.  
Our antibody inhibited tumor growth in a more relevant model, in which luciferase-positive BxPC-3 
cells were grafted in the pancreas of athymic mice. Despite a weak accessibility of tumors, 7E3 
antibody delays significantly their growth. Interestingly, in an orthotopic co-injection of BxPC-3 and 
CAFs models, our data clearly show that treatment with 7E3 inhibits tumor growth despite the 
enhanced aggressiveness of this model. It is indeed notable that co-injection of BxPC-3 and CAFs 
growth faster than cancer cell alone. These preclinical data are the first to describe in pancreatic 
cancer the therapeutic effect of targeting a growth factor expressed both in tumor cells and in micro-
environment (cancer associated fibroblast). The therapeutic efficiency of our 7E3 antibody used alone 
to delay tumor growth is comparable to earlier studies reported with Trap-Fc molecules or monoclonal 
antibodies [33. Finally, wound-healing assays showed that 7E3 reduces BxPC-3 and HPAC cell 
migration. Although additional studies are needed to confirm 7E3 therapeutic effect in metastatic 
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pancreatic cancer, an impact on epithelial-mesenchymal transition is especially suitable, since most 
pancreatic patients present with a metastatic disease at diagnosis [34, 35. 
NRG1 is the main HER3 ligand and promotes HER3/HER2 or HER3/EGFR dimerization, leading to 
the activation of PI3K/AKT and MAPK/ERK signaling pathways. Although we previously showed the 
interest to target HER2/HER3 dimers and HER3 in pancreatic cancer (36), the response rate to kinase 
inhibitors or monoclonal antibodies blocking HER signaling remains limited to weeks, before 
undergoing resistance process [37. Actually, clinical treatments combining chemotherapy and 
targeted therapies, such as erlotinib, provide no or modest benefit since patients rapidly acquire 
resistance. Several lines of evidence indicate the benefit to use an anti-NRG1 antibody such as 7E3 in 
this context to bypass this endless issue. First, the complex crosstalk between stromal components 
and tumor cells could have contributed to the failure of several clinical trials, particularly in pancreatic 
cancer that is characterized by a strong stromal component [37. Second, another possible 
mechanism of chemotherapy resistance is the stimulation of the ErbB/HER or Notch pathways through 
the upregulation of metalloproteinase-mediated cleavage of transmembrane ligands such as HER’s 
ligands [38-43. Finally, in other pathologies, acquired NRG1 expression also could drive resistance to 
targeted therapies, such as anti-HER3 antibodies in non-small cell lung cancer (NSCLC) [44, 45, 
cetuximab or vemurafenib in colorectal cancer [46, 47, or lapatinib in breast cancer [48.   
Knowing that the epitope of 7E3 is found in murine type I and II NRG1 sequences, we can deduce that 
7E3 can target the murine NRG1. No adverse effect on normal tissues of our anti-NRG1 antibody in 
the mouse models was observed. On the basis of its mechanisms of action, we can expect a favorable 
toxicity profile, as demonstrated for molecules targeting the NRG1 pathway, previously used in clinical 
trials [49. Phase 1 trials have shown that anti-HER3 agents are mainly efficient in patients with 
NRG1-activated tumors. Thus, combining HER3-targeted treatments with our anti-NRG1 antibody 
might increase the therapeutic index in ligand-activated cancers. Based on a previous report showing 
the potential of combining mutually non-competitive antibodies (against different epitopes from the 
same receptor), the association of 7E3 with an anti-HER3 antibody could be a promising approach 
[50. Eventually, considering the potential effect of combination therapies in pancreatic cancer 
treatment, studies on the effect of combining 7E3 with chemotherapy agents, such as gemcitabine or 
FOLFIRINOX, could pave the way for the development of 7E3-based treatment strategies for PDAC. 
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FIGURE LEGENDS 
 
Figure 1. NRG1 expression in pancreatic cancer cells and cancer-associated fibroblasts (CAFs).  
(A) RT-qPCR analysis of NRG1 mRNA levels in pancreatic tumor samples from patients who 
underwent surgical resection. Results are expressed as mRNA Arbitrary Units and normalized to the 
expression of the housekeeping gene HPRT. (B) NRG11 expression analysis by RT-qPCR and 
ELISA in the pancreatic cancer cells lines of AsPC-1, BxPC-3, CFPAC, HPAC, Mia-PaCa-2 and 
SW1990 and in AsPC-1-NRG1 cells that stably overexpress NRG1 and their conditioned medium. 
NPC are a mix of three normal pancreatic cells. NPF are normal pancreatic fibroblasts. Results are 
normalized to the expression of the housekeeping gene HPRT and expressed relatively to the lower 
cells expressing NRG1 (CFPAC=1). (C) Pro-tumor effect of NRG1 expressed and secreted by AsPC-
1-NRG1 cells. Proliferation of AsPC-1-NRG1 and AsPC-1-Mock cells was studied by counting cells for 
6 days (middle panel). AsPC-1-NRG1 and AsPC-1-Mock cells were xenografted in nude mice. Tumor 
growth was monitored every week, and at 40 days post-graft mice were sacrificed and tumors 
weighted (bottom panel). (D) SMA and vimentin expression by immunofluorescence analysis in 
CAFs from pancreatic cancer surgical biopsies or normal pancreatic fibroblasts (NPF) (top panels). (E) 
NRG1 mRNA was quantified by RT-qPCR in CAF cultures. Results are expressed as mRNA Arbitrary 
Units and normalized to HPRT expression. (F) The level of NRG1 secreted was measured in 
conditioned medium (CM) from CAF cultures grown in serum-free medium for 48h by ELISA assay. 
These CM was also added to serum-starved BxPC-3 cells for 15 minutes. The total level of 
phosphorylated HER3 was then measured by Western blotting (bottom panel). (*p<0.05; **p<0.01; 
***p<0.001). 
Figure 2. Characterization of the Ig-like domain-specific antibody 7E3. 
(A) SPR analysis of the binding kinetics between the anti-NRG1 antibody 7E3, rhNRG11-ECD and 
recombinant human HER3–Fc. HER3-Fc was captured on the sensor chip surface using an anti-
human Fc antibody, then 185nM rhNRG11-ECD was injected followed by an injection of 200nM of 
7E3 antibody. (B) Immunofluorescence detection of the 7E3 antibody on HER3-positive (shLuc) or 
HER3-silenced shHER3 BxPC-3 cells. Cells were serum-starved and then incubated with increasing 
concentrations of rhNRG11-ECD (1 to 100ng/ml) and 20 g/ml of 7E3 at 4°C for 1hour. Then, FITC-
conjugated goat anti-mouse IgGs were added. Anti-HER3 and anti-CEA antibodies were used as 
controls for HER3 and CEA expression. (C) Alanine scanning analysis to precisely identify 7E3 
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binding motif in the three membrane pentadecapeptides that correspond to the identified antibody-
immunoreactive sequences. Each bar represents 7E3 reactivity toward a pentadecapeptide sequence 
in which the indicated amino acid was substituted by alanine. The mean spot reactivity for each 
residue was calculated from the results obtained in the three pentadecapeptides using ImageJ. 
(D) Evaluation of 7E3-dependent ADCC activity against shHER3 or shLuc BxPC-3 cells by hPBMCs. 
Cells were first incubated or not with 50ng/ml rhNRG11-ECD and/or with 50µg/ml 7E3 or with the 
anti-HER2 antibody trastuzumab (positive control) at 37°C for 30min. Then, cells were incubated with 
hPBMC (37°C) at an effector:target ratio of 15:1 for 24h. BxPC-3 cell lysis was evaluated by 
measuring LDH release by bioluminescence. 
Figure 3. The 7E3 antibody inhibits NRG11-induced phosphorylation of HER3 and downstream 
signaling pathways and promotes HER3 downregulation. 
(A) BxPC-3 and MCF7 cells were starved for 24h, and then incubated for 15min with 15ng/ml 
rhNRG11-EDC and/or 3 to 100µg/ml 7E3 or 100μg/ml irrelevant antibody (IR). After cell lysis, the 
expression of phosphorylated and total HER3, AKT and ERK was analyzed by western blotting. (B) 
7E3 effect on HER4 phosphorylation was studied by western blotting in IGROV-1 cells following the 
same protocol as in A. (C) Internalization of 7E3 in BxPC-3 cells was detected by 
immunofluorescence. Cells were starved and co-incubated with rhNRG11-EDC and either with 7E3 
(4°C or 37°C) for different time points and then with FITC-conjugated goat anti-mouse IgGs, or with 
7E3 directly labelled with FITC. Control cells were incubated with FITC-conjugated goat anti-mouse 
IgGs. (D) HER3 expression in BxPC-3 cells was analyzed by Western blotting at different time points 
after incubation with 100 µg/ml 7E3 or irrelevant antibody (IR) together with 15ng/ml rhNRG11-EDC 
and was quantified relatively to tubulin levels (lower panels). 
Figure 4. The 7E3 antibody inhibits viability, growth and migration of pancreatic cancer cells. 
(A) Cell viability of BxPC-3 and HPAC cells was analyzed by using the sulforhodamine B assay. After 
serum starvation for 24h, cells were incubated for 5 days with 15 or 10 ng/ml rhNRG11-EDC, 
respectively, and with different concentrations of 7E3 or irrelevant antibody (IR). Results are presented 
as the percentage of cell viability relative to NRG11-treated cells (=100%). Each value represents the 
mean ± SEM of four experiments. (B) For 3D growth assays, BxPC-3 cells were seeded in Ultra Low 
Attachment plates to allow spheroid formation. After 10 days of growth in the presence of 50ng/ml 
rhNRG11-EDC and 50-100µg/ml 7E3 or irrelevant antibody (IR), spheroid cells were labeled with 
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calcein and fluorescence was measured with a Celigo Image Cytometer. (C) Wound healing assays 
using BxPC-3 and HPAC cells. After 24h of serum starvation, cells were wounded and wound healing 
was monitored in BxPC-3 and HPAC cells left untreated or stimulated for 48h with 15 or 10 ng/ml 
rhNRG11-ECD, respectively, together with 10 or 100 µg/ml of 7E3 when indicated. (D) After BxPC-3 
cell xenograft, mice were treated with 10 mg/kg 7E3 or irrelevant antibody (IR) twice per week for 4 
weeks. Results are presented as the mean tumor volume ± SEM for each group (n=10 animal per 
group). At day 48, all mice were killed and bioluminescence in pancreas measured. (*p<0.05; 
**p<0.01; ***p<0.001). (E)  BxPC-3-Luc cells were injected in the pancreas of nude mice. After 7 days, 
xenografted animals were treated for 6 weeks. Tumor growth was evaluated by measuring the emitted 
luminescence once per week after luciferin injection. Bioluminescence intensity (p/s) is presented as a 
function of treatment duration. (F) 7E3 antibody, but not saline, induced inhibition of MAPK and AKT 
phosphorylation in BxPC-3 xenograft after 2 weeks of treatment. GAPDH served as loading control.  
 
Figure 5. 7E3 inhibits 2D and 3D pancreatic cancer cell growth induced by pancreatic CAF- secreted 
NRG1.  
(A) Binding of 7E3 to CAFs isolated from PDAC specimens was assessed by immunofluorescence 
(X40). (B) HER3 phosphorylation in BxPC-3 cells upon incubation with conditioned medium (CM) from 
the indicated pancreatic CAF cultures without or with 100µg/ml of 7E3 or the irrelevant antibody (IR) 
was analyzed by western blotting. (C) Evaluation of 7E3-dependent ADCC activity against CAFs by 
hPBMCs. CAFs were incubated or not with 5µg/ml or 50µg/ml 7E3 or irrelevant antibody (IR) and 
hPBMC (effector:target ratio of 15:1) for 24h (37°C). CAF lysis was evaluated by measuring LDH 
release by bioluminescence. (D) After serum starvation for 24h, BxPC-3 cells were incubated with CM 
from CAF5, CAF6, CAF8 and CAF11 without or with 100µg/ml of 7E3 or the irrelevant antibody (IR). 
After 5 days, cell viability was tested with the sulforhodamine B assay (n=3). (E) HPAC cells 
transfected with luciferase (HPAC-Luc) were co-cultured with CAF11 cells (1/1) in ultra-low attachment 
plates and incubated with 7E3 or the irrelevant (IR) antibody. After 10 days, HPAC-Luc cell growth 
was analyzed by bioluminescence. (*p<0.05; **p<0.01; ***p<0.001). 
Figure 6. Effect of 7E3 on BxPC-3 tumor growth after co-injection of BxPC-3 cells and CAFs in the 
pancreas of athymic mice. 
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(A) BxPC-3 cells and CAFs (both NRG1-positive) were injected at a 1:2 ratio in the pancreas of 
athymic mice (n=10 per group). After 7 days, mice were treated or not (NT) with 10 mg/kg of 7E3 twice 
per week for 6 weeks. Tumor volume was measured by ultrasonography. Results are presented as the 
mean tumor volume for each group. (B) At the end of treatment, tumors were collected and weighed. 
(*p<0.05; **p<0.01; ***p<0.001). (C) Immunohistochemistry analysis shows the presence of SMA 
positive fibroblast and an increase of cleaved caspase3 in 7E3 treated tumors, but not in saline treated 
controls.  
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